Health Care [ 9/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
The company is headquartered in Fremont, California.
ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.13 Increased by +67.82% | - |
| Apr 15, 25 | 0.02 Increased by +105.10% | - |
| Nov 13, 24 | -0.01 Increased by +98.17% | - |
| Aug 14, 24 | -0.09 Increased by +86.93% | - |
| May 17, 24 | -0.40 Decreased by -573.33% | - |
| Mar 13, 24 | -0.39 Decreased by -161.20% | - |
| Nov 15, 23 | -0.82 Decreased by -643.73% | -0.04 Decreased by -1.95 K% |
| Aug 14, 23 | -0.68 Decreased by -1.04 K% | -0.06 Decreased by -1.04 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by -100.00% | -2.26 M Decreased by -122.81% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 1.97 K Increased by +63.07% | -842.00 K Increased by +70.29% | Decreased by -42.85 K% Increased by +81.78% |
| Dec 31, 24 | 1.97 K Decreased by -9.19% | 229.30 K Increased by +107.37% | Increased by +11.66 K% Increased by +108.12% |
| Sep 30, 24 | 389.28 K Increased by +2.35 K% | -186.56 K Increased by +94.38% | Decreased by -47.93% Increased by +99.77% |
| Jun 30, 24 | 117.14 K Increased by +1.82 K% | -1.01 M Increased by +55.26% | Decreased by -864.76% Increased by +97.67% |
| Mar 31, 24 | 1.21 K Decreased by -99.06% | -2.83 M Decreased by -55.41% | Decreased by -235.20 K% Decreased by -16.44 K% |
| Dec 31, 23 | 2.17 K Decreased by -99.63% | -3.11 M Increased by +36.04% | Decreased by -143.70 K% Decreased by -17.30 K% |
| Sep 30, 23 | 15.88 K Decreased by -62.42% | -3.32 M Increased by +10.44% | Decreased by -20.89 K% Decreased by -138.32% |